Deep Transcranial Magnetic Stimulation (TMS) With Paired Associative Stimulation (PAS) for the Treatment of Food Addiction in Obesity
NCT02761369, Not applicable, Unknown, Soroka University Medical Center
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Deep Transcranial Magnetic Stimulation (TMS) With Paired Associative Stimulation (PAS) for the Treatment of Food Addiction in Obesity | ClinicalTrials.gov |
| NCT number | NCT02761369 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Soroka University Medical Center | ClinicalTrials.gov |
| Conditions | Obesity | ClinicalTrials.gov |
| Interventions | A multi-channel deep TMS device with an H-coil (Brainsway Ltd) | ClinicalTrials.gov |
| First posted | 2016-05-04 | ClinicalTrials.gov |
| Last updated | 2018-01-03 | ClinicalTrials.gov |
Registered outcomes 8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in weight | Change in weight between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15) | Unit of measure: BMI in kg/m\^2 (weight in kilograms, height in meters) | ClinicalTrials.gov |
| Secondary | Performance on a food Stroop test | Change in performance between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15) | Unit of measure: reaction time (in milliseconds) | ClinicalTrials.gov |
| Secondary | Food addiction symptoms | Change between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15) | Yale Food Addiction Scale (YFAS) | ClinicalTrials.gov |
| Secondary | Safety and tolerability of a PAS protocol using the multi-channel deep TMS system, measured via the number of adverse events (AE) | Throughout the study period, estimated as 2 years | Measured via the number of adverse events | ClinicalTrials.gov |
| Secondary | Eating behavior (cognitive restraint, disinhibition, and hunger) | Change between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15) | Three Factor Eating Questionnaire (TFEQ) | ClinicalTrials.gov |
| Secondary | Quality of life | Change between baseline and the end of the treatment (day 15) and follow-up (a month after day 15) | Health Status Scale Short-form 36 (SF-36) | ClinicalTrials.gov |
| Secondary | Implementation of INP | Changes in cortical excitability between baseline versus following 15 days of treatment | 1\. Acute change in INP, assessed via changes in cortical excitability (measured via EEG and TCI) between pre- and post PAS administration. 2. Chronic change in INP assessed as change in cortical excitability between baseline versus the end of the treatment (day 15) and follow up (measured via EEG and TCI) | ClinicalTrials.gov |
| Other | General mood | Change between baseline versus the end of the treatment (day 15) and follow-up (a month after day 15) | Positive Affect Negative Affect Schedule (PANAS) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)